BLCO Stock Price, Bausch + Lomb Quote, Chart

Market Summary

USD14.90+0.05

Market Closed

0.34%

BLCO Stock Price

View Fullscreen

BLCO RSI Chart

BLCO Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

-20.11

Price/Sales (Trailing)

1.26

EV/EBITDA

18.9

Price/Free Cashflow

-26.41

BLCO Price/Sales (Trailing)

BLCO Profitability

EBT Margin

-4.00%

Return on Equity

-3.8%

Return on Assets

-1.93%

Free Cashflow Yield

-3.79%

BLCO Fundamentals

BLCO Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

17.77%

Rev. Growth (Qtr)

16.48%

BLCO Earnings

Earnings (TTM)

-260.0M

Earnings Growth (Yr)

-5.3K%

Earnings Growth (Qtr)

35.71%

Breaking Down BLCO Revenue

Last 7 days

4.1%

Last 30 days

-10.2%

Last 90 days

3.2%

Trailing 12 Months

-10.6%

How does BLCO drawdown profile look like?

BLCO Financial Health

Current Ratio

1.74

Debt/Equity

0.66

Debt/Cashflow

0

BLCO Investor Care

Shares Dilution (1Y)

0.28%

Diluted EPS (TTM)

-0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.8B	3.9B	4.0B	4.1B
2022	3.8B	3.8B	3.8B	3.8B
2021	3.5B	3.6B	3.7B	3.8B
2020	0	0	0	3.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bausch + Lomb Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	robertson russel c	acquired	25,621	17.3	1,481	-
Mar 29, 2024	paulson john	acquired	21,867	17.3	1,264	-
Mar 29, 2024	de schutter richard u	acquired	26,866	17.3	1,553	-
Mar 05, 2024	ling karen	acquired	-	-	2,642	-
Mar 01, 2024	bonnefoy luc	sold (taxes)	-18,084	16.47	-1,098	president,surgical
Mar 01, 2024	hashad yehia	sold (taxes)	-35,295	16.47	-2,143	evp of r&d and cmo
Mar 01, 2024	munsch frederick	sold (taxes)	-16,387	16.47	-995	svp, controller and cao
Mar 01, 2024	eldessouky sam	sold (taxes)	-79,945	16.47	-4,854	evp and cfo
Feb 28, 2024	saunders brent l	acquired	-	-	187,919	ceo and chair
Feb 28, 2024	munsch frederick	acquired	-	-	18,183	svp, controller and cao

Which funds bought or sold BLCO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	10.25	387,245	3,668,320	-%
Apr 16, 2024	Hodges Capital Management Inc.	sold off	-100	-3,155,000	-	-%
Apr 09, 2024	Renaissance Capital LLC	added	2.99	16,952	399,215	0.21%
Apr 05, 2024	CWM, LLC	unchanged	-	-	3,000	-%
Mar 27, 2024	NOMURA HOLDINGS INC	unchanged	-	138,180	21,430,400	0.05%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-25,968	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	2,390,820	2,390,820	-%
Feb 15, 2024	State of Wyoming	added	88.64	55,797	117,885	0.02%
Feb 15, 2024	BARCLAYS PLC	added	5,588	175,000	179,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	1,887	8,909,690	9,378,630	-%

Are Funds Buying or Selling BLCO?

Are funds buying BLCO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLCO

No. of Funds

Unveiling Bausch + Lomb Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	bausch health companies inc.	88.7%	310,449,643	SC 13G

Recent SEC filings of Bausch + Lomb Corporation

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 07, 2024	3	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading

Bausch + Lomb Corporation News

Latest updates

Bausch + Lomb Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	16.5%	1,173	1,007	1,035	931	996	942	941	889	1,001	949	934	881	-
Costs and Expenses	16.2%	1,124	967	992	933	945	896	885	835	909	855	876	796	-
S&GA Expenses	15.6%	483	418	417	418	386	381	368	343	365	348	358	318	-
EBITDA Margin	-0.3%	0.12*	0.12*	0.13*	0.14*	0.16*	0.17*	0.18*	0.18*	0.19*	0.20*	0.20*	0.21*	0.21*
Interest Expenses	30.3%	99.00	76.00	58.00	50.00	47.00	35.00	44.00	20.00	-	-	-	-	-
Income Taxes	-113.3%	-6.00	45.00	10.00	33.00	-2.00	34.00	20.00	6.00	32.00	25.00	21.00	47.00	-
Earnings Before Taxes	-62.9%	-57.00	-35.00	-19.00	-55.00	-2.00	19.00	27.00	29.00	86.00	88.00	67.00	77.00	-
EBT Margin	-43.2%	-0.04*	-0.03*	-0.01*	0.00*	0.02*	0.04*	0.06*	0.07*	0.08*	0.08*	0.08*	0.08*	0.08*
Net Income	35.7%	-54.00	-84.00	-32.00	-90.00	-1.00	-18.00	5.00	20.00	51.00	60.00	44.00	27.00	-
Net Income Margin	-20.2%	-0.06*	-0.05*	-0.04*	-0.03*	0.00*	0.02*	0.04*	0.05*	0.05*	0.00*	-0.01*	-0.01*	-0.01*
Free Cashflow	-560.0%	-69.00	15.00	-51.00	-93.00	109	-22.00	122	-39.00	100	232	205	143	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet									(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	2.9%	13,442	13,068	11,315	11,169	11,144	10,696	11,002	10,907	10,823
Current Assets	11.3%	2,742	2,464	2,315	2,184	2,137	1,859	2,001	1,719	1,635
Cash Equivalents	-6.8%	331	355	384	346	354	297	446	190	177
Inventory	36.3%	1,028	754	699	697	628	605	606	598	572
Net PPE	8.3%	1,390	1,284	1,294	1,296	1,300	1,222	1,243	1,225	1,225
Goodwill	19791.3%	4,575	23.00	4,540	4,522	4,507	4,415	4,493	4,553	4,586
Liabilities	5.4%	6,522	6,185	4,285	4,117	4,043	3,901	4,031	3,691	1,421
Current Liabilities	13.9%	1,579	1,386	1,325	1,254	1,296	1,199	1,273	1,092	1,099
Long Term Debt	2.2%	4,532	4,435	2,604	2,508	2,411	2,413	2,417	-	-
LT Debt, Current	0%	30.00	30.00	25.00	25.00	25.00	25.00	25.00	-	-
LT Debt, Non Current	2.2%	4,532	4,435	2,604	2,508	2,411	2,413	2,417	-	-
Shareholder's Equity	0.5%	6,850	6,817	7,030	7,052	7,033	6,795	6,971	7,216	9,402
Retained Earnings	-27.0%	-254	-200	-116	-84.00	6.00	7.00	25.00	20.00	-
Additional Paid-In Capital	0.2%	8,349	8,334	8,321	8,305	8,285	8,108	8,088	8,219	-
Shares Outstanding	0.0%	351	351	351	350	350	350	350	350	350
Minority Interest	6.1%	70.00	66.00	72.00	69.00	68.00	66.00	75.00	76.00	73.00
Float	-	-	-	802	-	-	-	603	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-68.7%	15,000	48,000	-24,000	-56,000	159,000	27,000	156,000	3,000	162,000	273,000	250,000	188,000	-
Share Based Compensation	0%	16,000	16,000	18,000	24,000	17,000	18,000	11,000	16,000	17,000	16,000	15,000	14,000	-
Cashflow From Investing	92.8%	-135,000	-1,882,000	-28,000	-64,000	-90,000	-49,000	-35,000	-41,000	-81,000	-40,000	-45,000	-48,000	-
Cashflow From Financing	-95.3%	86,000	1,811,000	90,000	91,000	-7,000	-109,000	145,000	52,000	-37,000	-378,000	-183,000	-114,000	-

BLCO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Total revenues	$ 4,146	$ 3,768	$ 3,765
Expenses
Selling, general and administrative (Note 3)	1,736	1,478	1,389
Research and development (Note 3)	324	307	271
Amortization of intangible assets	240	244	292
Other expense, net	74	13	17
Total expenses	4,016	3,561	3,436
Operating income	130	207	329
Interest income	15	6	0
Interest expense (Note 3)	(283)	(146)	0
Foreign exchange and other	(28)	6	(11)
(Loss) income before provision for income taxes	(166)	73	318
Provision for income taxes	(82)	(58)	(125)
Net (loss) income	(248)	15	193
Net income attributable to noncontrolling interest	(12)	(9)	(11)
Net (loss) income attributable to Bausch + Lomb Corporation	$ (260)	$ 6	$ 182
Basic (loss) income per share attributable to Bausch + Lomb Corporation (in usd per share)	$ (0.74)	$ 0.02	$ 0.52
Diluted (loss) income per share attributable to Bausch + Lomb Corporation (in usd per share)	$ (0.74)	$ 0.02	$ 0.52
Basic weighted-average common shares (in shares)	350.5	350.0	350.0
Diluted weighted-average common shares (in shares)	350.5	350.2	350.0
Product sales
Revenues
Total revenues	$ 4,131	$ 3,746	$ 3,737
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) (Note 3) and Cost of other revenues	1,640	1,511	1,458
Other revenues
Revenues
Total revenues	15	22	28
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) (Note 3) and Cost of other revenues	$ 2	$ 8	$ 9

BLCO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 331	$ 354
Restricted cash	3	26
Trade receivables, net (Note 3)	839	724
Inventories, net	1,028	628
Prepaid expenses and other current assets (Note 3)	541	405
Total current assets	2,742	2,137
Property, plant and equipment, net	1,390	1,300
Intangible assets, net	3,589	2,058
Goodwill	4,575	4,507
Deferred tax assets, net	921	927
Other non-current assets (Note 3)	225	215
Total assets	13,442	11,144
Current liabilities:
Accounts payable (Note 3)	522	370
Accrued and other current liabilities	1,027	901
Current portion of long-term debt	30	25
Total current liabilities	1,579	1,296
Deferred tax liabilities, net	14	7
Other non-current liabilities	397	329
Long-term debt	4,532	2,411
Total liabilities	6,522	4,043
Commitments and contingencies (Notes 20 and 21)
Equity
Common shares, no par value, unlimited shares authorized, 350,913,804 and 350,000,749 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	8,349	8,285
Accumulated (deficit) earnings	(254)	6
Accumulated other comprehensive loss	(1,245)	(1,258)
Total Bausch + Lomb Corporation shareholders’ equity	6,850	7,033
Noncontrolling interest	70	68
Total equity	6,920	7,101
Total liabilities and equity	$ 13,442	$ 11,144

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

CEO	Mr. Brenton L. Saunders J.D.
WEBSITE	bausch.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	13000

Bausch + Lomb Corporation Frequently Asked Questions

What is the ticker symbol for Bausch + Lomb Corporation? What does BLCO stand for in stocks?

BLCO is the stock ticker symbol of Bausch + Lomb Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch + Lomb Corporation (BLCO)?

As of Wed Apr 24 2024, market cap of Bausch + Lomb Corporation is 5.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart for subscribers.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart for subscribers. The fair value of Bausch + Lomb Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bausch + Lomb Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLCO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bausch + Lomb Corporation a good stock to buy?

The fair value guage provides a quick view whether BLCO is over valued or under valued. Whether Bausch + Lomb Corporation is cheap or expensive depends on the assumptions which impact Bausch + Lomb Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCO.

What is Bausch + Lomb Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, BLCO's PE ratio (Price to Earnings) is -20.11 and Price to Sales (PS) ratio is 1.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCO PE ratio will change depending on the future growth rate expectations of investors.